Abstract
We define “combination drugs” as “fixed-dose combinations” (FDCs), that is, two or more drugs (marketed or not) combined in a single pill or two or more separate drugs packaged together. FDCs have been available commercially for many years but only relatively recently have nonclinical development guidelines been released by a number of regulatory authorities and the World Health Organization; as yet there are no ICH guidelines specific to combination drugs. In general however, the ICH guidelines for monotherapy development provide a framework for FDC development. Depending on the type of drug combination (marketed drug/marketed drug; marketed drug/NME and NME/NME) the scope and complexity of toxicity studies will vary greatly. In all cases however, a key issue is the potential for pharmacokinetic and/or toxicologic interaction between the components. For a marketed drug/marketed drug combination a detailed review of the nonclinical data available may suffice, particularly when the components have a history of coadministration at about the same dose and ratio as that of the proposed combination. For a marketed drug/NME combination, in addition to a review of the data for the marketed drug, a full ICH program of studies will be required for the NME, and a study of up to 90-day duration (in one species) for the combination. With an NME/NME combination each component will require a full ICH battery of studies and a combination study in one species. In all cases additional studies may be needed to address data gaps. Given the many novel and complex issues which arise when developing FDCs we recommend that, whenever possible, the nonclinical study strategy is discussed with the regulatory authorities.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
FDA (2006) Nonclinical safety evaluation of drug or biologic combinations. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm079243.pdf
EMA (2008) Guideline on the non-clinical development of fixed combinations of medicinal products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500003976.pdf
TGA (2014) Fixed combination prescription medicines. https://www.tga.gov.au/fixed-combination-prescription-medicines
CADTH (2014) CADTH common drug review. Submission guidelines for the CADTH common drug review. https://www.cadth.ca/media/cdr/process/CDR_Submission_Guidelines.pdf
CDSCO (2010) Guidance for industry on fixed dose combinations (FDCs). http://www.cdsco.nic.in/writereaddata/FDC%20Guidelines%20_%20Revised1.pdf
FDA (2015) http://www.fda.gov/CombinationProducts/AboutCombinationProducts/ucm118332.htm
Segal SA (1999) Device and biologic combination products. Understanding the evolving regulation. Medical Device and Diagnostic Industry. January. pp 180–184
Portnoy S, Koepke K (2005) Regulatory strategy. Preclinical testing of combination products. Medical Device and Diagnostic Industry. May. pp 152–157
Herxheimer H (1975) The danger of fixed drug combinations. Int J Clin Pharmacol Biopharma 12(1–2):70–73
Shenfield GM (1982) Fixed combination drug therapy. Drugs. 23(6):462–480
Sica DA (2002) Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 62(3):443–462
Moulding T, Dutt AK, Reichman LB (1995) Fixed-dose combinations in antituberculous medications to prevent drug resistance. Ann Intern Med 122(12):955–956
Majori G (2004) Combined antimalarial therapy using artemisinin. Parasitologia 46(1–2):85–87
Fechtner RD, Realini T (2004) Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol 15(2):132–135
Prescott J, Manalo B (2011) Considerations for fixed-dose combination products in cardiometabolic disease. http://www.pharmacytimes.com/publications/issue/2011/December2011/Considerations-for-FixedDose-Combination-Products-in-Cardiometabolic-Disease
Kararli TT (2010) Fixed dose combination (fdc) products overview. http://www.pharmacircle.com/presentations/Fixed_Dose.pdf
Wertheimer A, Morrison A (2002) Combination drugs: innovation in pharmacotherapy. P&T 27(1):44–49
Hommer A (2011) Role of fixed combinations in the management of open-angle glaucoma. Exp Rev Pharmacoecon Outcomes Res. 11(1):91–99
American Thoracic Society (2015) What kind of medications are there for COPD? http://www.thoracic.org/copd-guidelines/for-patients/what-kind-of-medications-are-there-for-copd/what-are-combination-drugs.php
Kararli TT, Sedo K, Bossart J (2014a) Fixed-dose combination products—a review (part 1—introduction). http://www.drug-dev.com/Main/Back-Issues/FIXEDDOSE-COMBINATIONS-FixedDose-Combination-Produ-661.aspx
Kararli TT, Sedo K, Bossart J (2014b) Fixed-dose combination products—a review (part 2—analysis). http://www.drug-dev.com/Main/Back-Issues/FIXEDDOSE-COMBINATIONS-FixedDose-Combination-Produ-673.aspx
Kararli TT, Sedo K, Bossart J (2014c) Fixed-dose combination products—what’s in the clinic? (part 3—pipeline). http://www.drug-dev.com/Main/Back-Issues/FIXEDDOSE-COMBINATIONS-FixedDose-Combination-Produ-673.aspx
ICH Guidelines (2007) http://www.ich.org/home.html
ICH (2009) Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3(R2). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M3_R2/Step4/M3_R2__Guideline.pdf
ICH (2012) M3(R2) Implementation Working Group M3(R2) guideline: guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. Questions & answers (R2). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M3_R2/Q_As/M3_R2_Q_A_R2_Step4.pdf
FDA (2013) Guidance for industry. Codevelopment of two or more new investigational drugs for use in combination. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM236669.pdf
FDA (2006) Fixed dose combinations, co-packaged drug products, and single-entity versions of previously approved antiretrovirals for the treatment of HIV. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM079742.pdf
Liminga U, Silva L (2003) Non-clinical development of fixed combinations. A European regulatory perspective. Int J. Pharm Med 18(3):135–138
Japanese Pharmaceutical Association (2015) Pharmaceutical administration and regulations in Japan. http://www.jpma.or.jp/english/parj/pdf/2015.pdf
Hunt L (2003) Fixed-combination medicines: an Australian perspective. WHO Drug Inform 2:110–112
Therapeutic Products Directorate (2000) Guidelines for preparation of new drug submissions for products used for estrogen-progestin replacement therapy in menopause (HRT). http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/hrt-ths/hrt_ths-eng.php
WHO (2005) WHO Expert Committee on Specifications for Pharmaceutical Preparations Guidelines for registration of fixed-dose combination medicinal products Technical Report Series. WHO Tech Rep Ser 929:93–142
Rogge MC, Taft DR (eds) (2005) Preclinical drug development. Taylor & Francis Group, Boca Raton, FL
CDER. Medical review for Kaletra. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-251S003_Kaletra.cfm.
ICH (2000) Safety pharmacology studies for human pharmaceuticals S7A. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7A/Step4/S7A_Guideline.pdf
FDA (2000) DRAFT ICH Consensus principle for clinical evaluation of new antihypertensive drugs E12A. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E12/Step4/E12_Guideline.pdf
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Lodola, A. (2017). Nonclinical Development of Combination Drugs. In: Gautier, JC. (eds) Drug Safety Evaluation. Methods in Molecular Biology, vol 1641. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7172-5_1
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7172-5_1
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7170-1
Online ISBN: 978-1-4939-7172-5
eBook Packages: Springer Protocols